Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.
2.

Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.

Lapidus LJ, Rosfors S, Ponzer S, Levander C, Elvin A, Lärfars G, de Bri E.

J Orthop Trauma. 2007 Jan;21(1):52-7.

PMID:
17211270
3.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

4.

Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).

Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J; ECHOS Trial Group.

Int Angiol. 2006 Dec;25(4):335-42.

PMID:
17164738
5.

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G.

N Engl J Med. 1998 Feb 12;338(7):409-15.

6.

Clinical inquiries. Does anticoagulation prevent thrombosis for persons with fractures distal to the hip?

Brogen J, Kelsberg G, Safranek S, Nadalo D, Janki P.

J Fam Pract. 2005 Apr;54(4):376-7. Review.

PMID:
15833234
7.

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.

Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al.

N Engl J Med. 1993 Nov 4;329(19):1370-6.

8.

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization.

Zee AA, van Lieshout K, van der Heide M, Janssen L, Janzing HM.

Cochrane Database Syst Rev. 2017 Aug 6;8:CD006681. doi: 10.1002/14651858.CD006681.pub4. Review.

9.

Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury.

Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N, Mismetti P, Sautet A, Barrellier MT, Apartsin K, Jonas M, Caeiro JR, van der Veen AH, Roy PM; FONDACAST Study Group.

J Thromb Haemost. 2013 Oct;11(10):1833-43. doi: 10.1111/jth.12395.

10.

Reviparin sodium - a new low molecular weight heparin.

Breddin HK.

Expert Opin Pharmacother. 2002 Feb;3(2):173-82. Review.

PMID:
11829731
11.

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.

Testroote M, Stigter W, de Visser DC, Janzing H.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006681. doi: 10.1002/14651858.CD006681.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD006681.

PMID:
18843725
12.

Intermittent pneumatic compression reduces the risk of deep vein thrombosis during post-operative lower limb immobilisation: a prospective randomised trial of acute ruptures of the Achilles tendon.

Domeij-Arverud E, Labruto F, Latifi A, Nilsson G, Edman G, Ackermann PW.

Bone Joint J. 2015 May;97-B(5):675-80. doi: 10.1302/0301-620X.97B5.34581.

PMID:
25922463
13.

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.

Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF.

Arch Intern Med. 2000 Jan 24;160(2):229-36.

PMID:
10647762
14.

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.

Testroote M, Stigter WA, Janssen L, Janzing HM.

Cochrane Database Syst Rev. 2014 Apr 25;(4):CD006681. doi: 10.1002/14651858.CD006681.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Aug 06;8:CD006681.

PMID:
24771319
15.

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group.

Circulation. 2004 Aug 17;110(7):874-9. Epub 2004 Aug 2.

16.

[Thrombosis prevention in outpatients with lower limb injuries].

Kujath P, Spannagel U, Habscheid W, Schindler G, Weckbach A.

Dtsch Med Wochenschr. 1992 Jan 3;117(1):6-10. German.

PMID:
1309691
17.

Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.

Adolf J, Fritsche HM, Haas S, Hennig FF, Horbach T, Kastl S, Koppenhagen K, Michaelis HC, Rhamanzadeh R, Summa W, Wagner W, Weber U, Wolf H.

Int Angiol. 1999 Jun;18(2):122-6.

PMID:
10424367
18.

Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.

Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G, Petersen AO, Siem P, Hørlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Møller JC, Rotwitt L, Christensen F, Nielsen JB, Jørgensen PS, Paaske B, Tørholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E, et al.

Thromb Res. 1998 Mar 15;89(6):281-7.

PMID:
9669750
19.
20.

Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.

Lapidus LJ, Ponzer S, Elvin A, Levander C, Lärfars G, Rosfors S, de Bri E.

Acta Orthop. 2007 Aug;78(4):528-35.

PMID:
17966008

Supplemental Content

Support Center